Interestingly, the DATA study showed that patients with tumours expressing only one hormone receptor did not benefit from extended endocrine treatment (HR 1.22; 95% CI 0.86–1.73), whereas patients with tumours expressing both hormone receptors did experience a large benefit (HR 0.77; 95% CI 0.63–0.93) (p interaction = 0.018). Here, NR4A1 is linked to neoplasm.